Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.68 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.67 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.67 |
| ▸ | CTSL | P07711 | 2/20 | 0.67 |
| ▸ | CTSB | P07858 | 2/20 | 0.67 |
| ▸ | CTSS | P25774 | 2/20 | 0.67 |
| ▸ | CTSK | P43235 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.64 |
| ▸ | MME | P08473 | 1/20 | 0.62 |
| ▸ | ECE1 | P42892 | 1/20 | 0.62 |
| ▸ | TYR | P14679 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7372270 | 1.00 | TACR1 (0.68) | TACR1ITGB3ITGA2BCTSLCTSB | |
| SCHEMBL219151 | 1.00 | TACR1 (0.68) | TACR1ITGB3ITGA2BCTSLCTSB | |
| SCHEMBL220648 | 1.00 | TACR1 (0.68) | TACR1ITGB3ITGA2BCTSLCTSB | |
| SCHEMBL26661077 | 1.00 | TACR1 (0.68) | TACR1ITGB3ITGA2BCTSLCTSB | |
| Hypochlorous Acid SCHEMBL7368156 | 0.97 | TACR1 (0.65) | TACR1ITGB3ITGA2BCTSLCTSB | |
| SCHEMBL5391083 | 0.94 | ITGB3 (0.65) | TACR1ITGB3ITGA2BCTSLCTSB | |
| SCHEMBL12052836 | 0.94 | TACR1 (0.70) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL1702159 | 0.94 | ECE1 (0.65) | TACR1ITGB3ITGA2BCTSLCTSB | |
| SCHEMBL221300 | 0.94 | ECE1 (0.65) | TACR1ITGB3ITGA2BCTSLCTSB | |
| SCHEMBL10507966 | 0.94 | ECE1 (0.65) | TACR1ITGB3ITGA2BCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 415 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728167-B2 | Process for the preparation of enantiomerically enriched amino acids | DEGUSSA AG (DE) | 2010-06-01 | — | — | US | claimed |
| US-20080015368-A1 | Process for preparing beta-amino-alpha-hydroxycarboxamides | DEGUSSA GMBH (DE) | 2008-01-17 | — | — | US | claimed |
| US-6646130-B2 | Comprises mixtures of alky esters of 3-(6-methoxy-pyridin-3-yl); for inhibiting bone resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammatory arthritis, cancer, and metastasis | MERCK & CO., INC. | 2003-11-11 | — | — | US | claimed |
| US-6395077-B1 | INKS WITH BENZOYLBENZOIC ACID AND COLORS | XEROX CORPORATION | 2002-05-28 | — | — | US | claimed |
| EP-1039886-A4 | HIV/FIV PROTEASE INHIBITORS HAVING A SMALL P3 RESIDUE | SCRIPPS RESEARCH INST (US) | 2001-05-16 | — | — | EP | claimed |
| EP-0817795-B1 | NOVEL 4-SUBSTITUTED-3-PEPTIDYL-AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE INHIBITOR | NAEJA PHARMACEUTICAL INC (CA) | 2000-11-15 | — | — | EP | claimed |
| EP-1039886-A1 | HIV/FIV PROTEASE INHIBITORS HAVING A SMALL P3 RESIDUE | The Cripps Research Institute (US) | 2000-10-04 | — | — | EP | claimed |
| US-5986108-A | ENZYME INHIBITORS | SYNPHAR LABORATORIES, INC. (CA) | 1999-11-16 | — | — | US | claimed |
| WO-1999029311-A1 | HIV/FIV PROTEASE INHIBITORS HAVING A SMALL P3 RESIDUE | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-06-17 | — | — | WO | claimed |
| US-5757408-A | PRINTING IMAGE ON SUBSTRATE COATED WITH AMINO-ACID DERIVATIVE ADDITIVE; QUICK DRYING OF INK, OPTICAL DENSITY, NONCURLING | XEROX CORPORATION (US) | 1998-05-26 | — | — | US | claimed |
| EP-0817795-A1 | NOVEL 4-SUBSTITUTED-3-PEPTIDYL-AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE INHIBITOR | SYNPHAR LABORATORIES INC. (CA) | 1998-01-14 | — | — | EP | claimed |
| US-5683793-A | Ink jet transparencies | XEROX CORPORATION (US) | 1997-11-04 | — | — | US | claimed |
| US-5589277-A | INK JET PRINTING, AQUEOUS INKS, FAST DRYING | XEROX CORPORATION (US) | 1996-12-31 | — | — | US | claimed |
| WO-1996032408-A1 | NOVEL 4-SUBSTITUTED-3-PEPTIDYL-AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE INHIBITOR | SYNPHAR LABORATORIES, INC. (US) | 1996-10-17 | — | — | WO | claimed |
| EP-0667246-A1 | Recording sheets containing amino acids, hydroxy acids, and polycarboxyl compounds | XEROX CORPORATION (US) | 1995-08-16 | — | — | EP | claimed |
| JP-62269689-A | — | — | None | — | — | JP | disclosed |
| JP-3038553-A | — | — | None | — | — | JP | disclosed |
| US-4076703-A | 2-O-CHLOROBENZOYL-4-CHLORO-N-METHYL-N(ALPHA)-GLYCYL-GLYCINANILIDE | SHIONOGI & CO., LTD. (JA) | 1978-02-28 | — | — | US | disclosed |
| US-4059603-A | Esterification of carboxylic acids by contact with a phosphonium salt | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1977-11-22 | — | — | US | disclosed |
| US-3974219-A | PREPARATION PEPTIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1976-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015368-A1 | Process for preparing beta-amino-alpha-hydroxycarboxamides | BCAT1, ASPH, BCAT2 | TACR1 3157/4885ITGB3 3593/4885ITGA2B 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.